<DOC>
	<DOCNO>NCT02391116</DOCNO>
	<brief_summary>To assess potential efficacy ( term objective response ) single agent copanlisib patient relapse refractory Diffuse large B-cell lymphoma ( DLBCL ) ass relationship efficacy potentially predictive biomarker</brief_summary>
	<brief_title>Phase II Copanlisib Relapsed/Refractory Diffuse Large B-cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Diagnosis Diffuse large Bcell lymphoma ( DLBCL ) ( de novo DLBCL transform follicular lymphoma basis tissue biopsy ) . Received least one prior therapy aggressive NonHodgkin 's Lymphoma ( NHL ) ( DLBCL ) Patients must measurable disease . ECOG ( Eastern Cooperative Oncology Group ) performance status ( PS ) ≤ 2 Left ventricular ejection fraction ( LVEF ) ≥ low limit normal ( LLN ) Institution ( per local standard care ) measure echocardiogram ( ECHO ) Multiple gated acquisition ( MUGA ) scan Adequate bone marrow , liver renal function . Any following site ( ) disease : palpable lymph node visible image study , skin lesion , bone marrow involvement Active CTCAE ( Common Terminology Criteria Adverse Events ) Grade 3/4 infection Known history human immunodeficiency virus ( HIV ) infection Current central nervous system ( CNS ) involvement lymphoma Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction within past 6 month start study treatment Type I II diabetes mellitus HbA1c &gt; 8.5 % fast plasma glucose &gt; 160 mg/dL Screening . New York Heart Association ( NYHA ) class III IV heart disease Concurrent participation clinical study . Patients previously receive therapy copanlisib PI3K inhibitor eligible enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>